{"id":203,"date":"2018-08-29T00:16:46","date_gmt":"2018-08-29T00:16:46","guid":{"rendered":"https:\/\/www.ladrxcorp.com\/?page_id=203"},"modified":"2022-09-26T20:36:34","modified_gmt":"2022-09-26T20:36:34","slug":"about-us","status":"publish","type":"page","link":"https:\/\/www.ladrxcorp.com\/about-us\/","title":{"rendered":"About Us"},"content":{"rendered":"<div id=\"cs-content\" class=\"cs-content\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LadRx Corporation OverviewLadRx is a biopharmaceutical company focused on discovering and developing new therapeutics to treat patients with high unmet needs. LadRx has a milestone and royalty agreement with Orphazyme A\/S (Nasdaq &#8211; &#8220;ORPH&#8221;) for &#8230; <a href=\"https:\/\/www.ladrxcorp.com\/about-us\/\" class=\"more-link\">Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-layout-sidebar-content.php","meta":[],"_links":{"self":[{"href":"https:\/\/www.ladrxcorp.com\/wp-json\/wp\/v2\/pages\/203"}],"collection":[{"href":"https:\/\/www.ladrxcorp.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ladrxcorp.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ladrxcorp.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ladrxcorp.com\/wp-json\/wp\/v2\/comments?post=203"}],"version-history":[{"count":10,"href":"https:\/\/www.ladrxcorp.com\/wp-json\/wp\/v2\/pages\/203\/revisions"}],"predecessor-version":[{"id":1538,"href":"https:\/\/www.ladrxcorp.com\/wp-json\/wp\/v2\/pages\/203\/revisions\/1538"}],"wp:attachment":[{"href":"https:\/\/www.ladrxcorp.com\/wp-json\/wp\/v2\/media?parent=203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}